New insights into the Bortezomib-induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model

Hematol Oncol. 2024 Mar;42(2):e3262. doi: 10.1002/hon.3262.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antineoplastic Agents* / adverse effects
  • Bortezomib / pharmacology
  • Humans
  • Lymphoma, Primary Effusion* / drug therapy
  • Mice

Substances

  • Bortezomib
  • Antineoplastic Agents